12 results
6-K
EX-10.1
CLYYF
Celyad Oncology SA
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
Laundering
Critical Technologies
Title
Intellectual Property Rights
Cybersecurity
Compliance with Data Privacy Laws
Employee Agreements
Environmental … ), other than the Permitted Encumbrances, on any Company Patent.
4.28 Cybersecurity. There has been no security breach or incident, unauthorized
6-K
EX-10.3
CLYYF
Celyad Oncology SA
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
Technologies
Title
Intellectual Property Rights
Cybersecurity
Compliance with Data Privacy Laws
Employee Agreements
Environmental Laws
Insurance
Tax Status … (including march-in rights), other than the Permitted Encumbrances, on any Company Patent.
4.28
Cybersecurity
There has been no security breach
6-K
EX-10.1
CLYYF
Celyad Oncology SA
3 Dec 21
Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group
9:19am
Act
4.23 Economic Sanctions
4.24 Money Laundering
4.25 Critical Technologies
4.26 Title
4.27 Intellectual Property Rights
4.28 Cybersecurity … Cybersecurity. There has been no security breach or incident, unauthorized access or disclosure, or other compromise of or relating to the Company’s
6-K
EX-10.1
mgx8mr9ftx9i2w1
7 Jan 21
Celyad Oncology Announces Equity Purchase Agreement for up to $40 Million with Lincoln Park Capital
7:29am
424B5
d8d ohzjs5ihr2
7 Jan 21
Prospectus supplement for primary offering
7:28am
6-K
EX-1.1
7eha8
11 Sep 20
Current report (foreign)
5:17pm
424B5
drf1 en4v
11 Sep 20
Prospectus supplement for primary offering
5:13pm
F-3
o0q1yzx4gje4yrfwt
28 Aug 20
Shelf registration (foreign)
4:02pm
6-K
EX-1.1
dhmls 2cn
12 Sep 19
Current report (foreign)
5:17pm
- Prev
- 1
- Next